Effects of Corticosteroid Treatment for Non-Severe COVID-19 Pneumonia: A Propensity Score-Based Analysis

Shock - Tập 54 Số 5 - Trang 638-643 - 2020
Mingli Yuan1,2, Xiaoxiao Xu1,2, Dongping Xia1,2, Tao Zeng1,2, Wen Yin1,2, Weijun Tan1,2, Yi Hu1,2, Cheng Song3,1,2
1Department of Pulmonary and Critical Care Medicine, Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
2Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal's Web site (www.shockjournal.com).
3Address reprint requests to Cheng Song, MD, Department of Pulmonary and Critical Care Medicine, Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province 430013, China. E-mail: [email protected]

Tóm tắt

ABSTRACT Background and objective: The effects of corticosteroid treatment on non-severe COVID-19 pneumonia patients are unknown. To determine the impacts of adjuvant corticosteroid administrated to patients with non-severe COVID-19 pneumonia. Method: A retrospective cohort study based on propensity score analysis was designed to explore the effects of corticosteroid on several clinical outcomes. Results: One hundred thirty-two patients satisfied the inclusion criteria and 35 pairs were generated according to propensity score matching. Compared to non-corticosteroid group, the CT score on day 7 was significantly higher in corticosteroid group (8.6 (interquartile range [IQR], 2.8–11.5) versus 12.0 (IQR, 5.0–19.3), P = 0.046). In corticosteroid group, more patients progressed to severe cases (11.4% versus 2.9%, P = 0.353), hospital stay (23.5 days (IQR, 19–29 d) versus 20.2 days (IQR, 14–25.3 d), P = 0.079) and duration of viral shedding (20.3 days (IQR, 15.2–24.8 d) versus 19.4 days (IQR, 11.5–28.3 d), P = 0.669) were prolonged, while fever time (9.5 days (IQR, 6.5–12.2 d) versus 10.2 days (IQR, 6.8–14 d), P = 0.28) was shortened; however, all these data revealed no statistically significant differences. Conclusion: Corticosteroid might have a negative effect on lung injury recovery in non-severe COVID-19 pneumonia patients; however, the results of this study must be interpreted with caution because of confounding factors.

Từ khóa


Tài liệu tham khảo

Yin, 2018, MERS, SARS and other coronaviruses as causes of pneumonia, Respirology, 23, 130, 10.1111/resp.13196

Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5

Chen, 2020, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet, 395, 507, 10.1016/S0140-6736(20)30211-7

Li, 2020, Early transmission dynamics in wuhan, china, of novel coronavirus-infected pneumonia, N Engl J Med, 382, 1199, 10.1056/NEJMoa2001316

Russell, 2020, Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury, Lancet, 395, 473, 10.1016/S0140-6736(20)30317-2

Shang, 2020, On the use of corticosteroids for 2019-nCoV pneumonia, Lancet V 395, 683, 10.1016/S0140-6736(20)30361-5

Zhao, 2020, [Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia], Zhonghua Jie He He Hu Xi Za Zhi, 43, 183

Feng, 2014, Association of radiologic findings with mortality in patients with avian influenza H7N9 pneumonia, PLoS One, 9, e93885, 10.1371/journal.pone.0093885

Yuan, 2020, Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China, PLoS One, 15, e0230548, 10.1371/journal.pone.0230548

Bangalore, 2015, Everolimus-eluting stents or bypass surgery for multivessel coronary disease, N Engl J Med, 372, 1213, 10.1056/NEJMoa1412168

Wu, 2020, Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China, JAMA Intern Med, e200994

Arabi, 2017, Middle east respiratory syndrome, N Engl J Med, 376, 584, 10.1056/NEJMsr1408795

2003, Dynamic changes in blood cytokine levels as clinical indicators in severe acute respiratory syndrome, Chin Med J (Engl), 116, 1283

Zhou, 2020, Use of corticosteroids in influenza-associated acute respiratory distress syndrome and severe pneumonia: a systemic review and meta-analysis, Sci Rep, 10, 3044, 10.1038/s41598-020-59732-7

Li, 2017, Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia, Influenza Other Respir Viruses, 11, 345, 10.1111/irv.12456

Stockman, 2006, SARS: systematic review of treatment effects, PLoS Med, 3, e343, 10.1371/journal.pmed.0030343

Chen, 2006, Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience, Chest, 129, 1441, 10.1378/chest.129.6.1441

Arabi, 2018, Corticosteroid therapy for critically ill patients with middle east respiratory syndrome, Am J Respir Crit Care Med, 197, 757, 10.1164/rccm.201706-1172OC

Wang, 2020, Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China, MedRxiv

Lee, 2004, Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients, J Clin Virol, 31, 304, 10.1016/j.jcv.2004.07.006

Vaduganathan, 2020, Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19, N Engl J Med, 382, 1653, 10.1056/NEJMsr2005760

Mendelsohn, 1982, Induction by glucocorticoids of angiotensin converting enzyme production from bovine endothelial cells in culture and rat lung in vivo, J Clin Invest, 70, 684, 10.1172/JCI110663

Ullian, 1999, The role of corticosteroids in the regulation of vascular tone, Cardiovasc Res, 41, 55, 10.1016/S0008-6363(98)00230-2

Fang, 2020, Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19, J Infect, 81, 147

Zou, 2020, SARS-CoV-2 viral load in upper respiratory specimens of infected patients, N Engl J Med, 382, 1177, 10.1056/NEJMc2001737

Thông tin
Thông tin xuất bản

Shock

Tập 54 Số 5

638-643

Thông tin tác giả